summary: In 2007, a clinical trial of glatiramer acetate (GA, Copaxone®) in primary progressive MS (PPMS) was carried out. Though GA did not turn out to be effective in PPMS, when only the male population was observed, some hints of efficacy of GA were suggested. In this article the authors aimed to investigate whether the effect of GA during the clinical trial could have caused different effects in men and in women. However, the authors finally concluded that GA would seem to have caused the same (not significant) clinical effects in men and women. Then, if some differences between both sexes were observed during the trial, these should be attributed to other incidental clinical factors apart from gender.

authors: Wolinsky JS, Shochat T, Weiss S, Ladkani D; for the PROMiSe Trial Study Group

source: J Neurol Sci. 2009 May 7

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: